Earnings season marches on, and we're here to spotlight the companies set to unveil their financial results in the next trading day. As Friday approaches, investors are eagerly anticipating reports ...

AbbVie (ABBV) is expected to beat Q4 earnings estimates with strong performance from key products, including Skyrizi and Rinvoq.

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...